Neoadjuvant therapy trials in biliary tract malignancies.
作者信息
Medin Caroline R, Maithel Shishir K
机构信息
Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
出版信息
J Surg Oncol. 2022 Jan;125(1):84-88. doi: 10.1002/jso.26714.
Abstract
摘要
相似文献
1
Neoadjuvant therapy trials in biliary tract malignancies.胆道恶性肿瘤的新辅助治疗试验
J Surg Oncol. 2022 Jan;125(1):84-88. doi: 10.1002/jso.26714.
2
Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer.可切除胆管癌的辅助和新辅助治疗的作用。
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):537-545. doi: 10.1080/17474124.2021.1911645. Epub 2021 Apr 13.
3
Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials.胆道癌辅助治疗的进展：基于 II 期和 III 期临床试验的现有临床证据概述。
Crit Rev Oncol Hematol. 2020 Jul;151:102975. doi: 10.1016/j.critrevonc.2020.102975. Epub 2020 Apr 27.
4
Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.胆道癌的辅助和新辅助治疗：临床试验综述。
Jpn J Clin Oncol. 2020 Dec 16;50(12):1353-1363. doi: 10.1093/jjco/hyaa170.
5
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.胆道癌切除术后辅助治疗：ASCO 临床实践指南。
J Clin Oncol. 2019 Apr 20;37(12):1015-1027. doi: 10.1200/JCO.18.02178. Epub 2019 Mar 11.
6
Adjuvant and neoadjuvant chemotherapy for biliary tract cancer: a review of randomized controlled trials.辅助和新辅助化疗治疗胆道癌：随机对照试验综述。
Jpn J Clin Oncol. 2023 Nov 5;53(11):1019-1026. doi: 10.1093/jjco/hyad103.
7
[Management of biliary tract carcinomas].[胆管癌的管理]
Rev Prat. 2009 Apr 20;59(4):469-73.
8
Multimodality Management of Localized Biliary Cancer.局部胆癌的多模态管理。
Curr Treat Options Oncol. 2019 May 29;20(7):58. doi: 10.1007/s11864-019-0655-0.
9
Adjuvant therapy for resected biliary tract cancer: a review.切除术后胆道癌的辅助治疗：综述
Chin Clin Oncol. 2016 Oct;5(5):64. doi: 10.21037/cco.2016.08.05. Epub 2016 Sep 5.
10
The Landmark Series: Gallbladder Cancer.地标系列：胆囊癌。
Ann Surg Oncol. 2020 Aug;27(8):2846-2858. doi: 10.1245/s10434-020-08654-9. Epub 2020 May 30.
引用本文的文献
1
LI-RADS Category Can Be a Post-Surgical Prognostic Factor for Intrahepatic Cholangiocarcinoma in Patients with Liver Cirrhosis or Chronic Hepatitis B.肝脏影像报告和数据系统（LI-RADS）分类可作为肝硬化或慢性乙型肝炎患者肝内胆管癌的术后预后因素。
Liver Cancer. 2024 Jun 14;13(6):629-642. doi: 10.1159/000539794. eCollection 2024 Dec.
2
Efficacy of neoadjuvant therapy and lymph node dissection in advanced gallbladder cancer without distant metastases: a SEER database analysis.新辅助治疗和淋巴结清扫术在无远处转移的晚期胆囊癌中的疗效：一项监测、流行病学和最终结果（SEER）数据库分析
Front Oncol. 2024 Nov 25;14:1511583. doi: 10.3389/fonc.2024.1511583. eCollection 2024.
3
Clinicopathological and Molecular Insights into Gallbladder Cancer.胆囊癌的临床病理及分子研究进展
Cancers (Basel). 2023 May 12;15(10):2728. doi: 10.3390/cancers15102728.
4
Gallbladder cancer: current and future treatment options.胆囊癌：当前及未来的治疗选择
Front Pharmacol. 2023 May 11;14:1183619. doi: 10.3389/fphar.2023.1183619. eCollection 2023.
本文引用的文献
1
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with rearrangements.FIGHT-302 研究：一线吡咯替尼对比吉西他滨联合顺铂治疗伴有基因重排的晚期胆管癌
Future Oncol. 2020 Oct;16(30):2385-2399. doi: 10.2217/fon-2020-0429. Epub 2020 Jul 17.
2
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.评估氟尿苷肝动脉灌注联合全身吉西他滨和奥沙利铂治疗不可切除的肝内胆管细胞癌患者的疗效：一项 2 期临床试验。
JAMA Oncol. 2020 Jan 1;6(1):60-67. doi: 10.1001/jamaoncol.2019.3718.
3
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.TAS-120 克服 FGFR2 融合阳性肝内胆管癌患者对 ATP 竞争性 FGFR 抑制剂的耐药性。
Cancer Discov. 2019 Aug;9(8):1064-1079. doi: 10.1158/2159-8290.CD-19-0182. Epub 2019 May 20.
4
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.吉西他滨、顺铂和 nab-紫杉醇治疗晚期胆道癌：一项 2 期临床试验。
JAMA Oncol. 2019 Jun 1;5(6):824-830. doi: 10.1001/jamaoncol.2019.0270.
5
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.卡培他滨对比观察用于可切除胆管癌（BILCAP）：一项随机、对照、多中心、3 期研究。
Lancet Oncol. 2019 May;20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X. Epub 2019 Mar 25.
6
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.胆道癌切除术后辅助治疗：ASCO 临床实践指南。
J Clin Oncol. 2019 Apr 20;37(12):1015-1027. doi: 10.1200/JCO.18.02178. Epub 2019 Mar 11.
7
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring Gene Alterations.一项 I 期、开放性、多中心、剂量递增研究，评估口服选择性 FGFR 抑制剂 Debio 1347 用于携带 基因改变的晚期实体瘤患者。
Clin Cancer Res. 2019 May 1;25(9):2699-2707. doi: 10.1158/1078-0432.CCR-18-1959. Epub 2019 Feb 11.
8
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.吉西他滨和奥沙利铂化疗或监测在切除的胆管癌 (PRODIGE 12-ACCORD 18-UNICANCER GI)：一项随机 III 期研究。
J Clin Oncol. 2019 Mar 10;37(8):658-667. doi: 10.1200/JCO.18.00050. Epub 2019 Feb 1.
9
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.达拉替尼（ARQ 087）治疗晚期或不可切除的 FGFR2 基因融合阳性肝内胆管癌。
Br J Cancer. 2019 Jan;120(2):165-171. doi: 10.1038/s41416-018-0334-0. Epub 2018 Nov 13.
10
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.BGJ398 治疗 FGFR 改变的晚期胆管癌患者的 II 期研究。
J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.
Zotero 插件